Grail's Share Price Continues Decline Amid Disappointing Trial Results

Grail (NASDAQ: GRAL) has seen its share price fall over 20% in 2026 after missing a primary endpoint in a three-year trial for its multicancer early detection test, Galleri. The underwhelming results have raised concerns about FDA approval and insurance coverage prospects.

By Lee Samaha · Motley Fool · May 25, 2026, 12:00 UTC

Grail's Share Price Continues Decline Amid Disappointing Trial Results

Tickers: $GRAL

Topics: cancer detection FDA approval stock price movement

Read the full article at Motley Fool

More Health news

Data Suggests United States May Lose Measles Elimination Status The Verge · November 11, 2026, 19:48 UTC
Rising U.S. Measles Outbreaks Pose Significant Economic Burden CNBC · November 11, 2026, 12:00 UTC
FDA Issues Not Approvable Letter for NovoCure's Optune Mya Motley Fool · November 10, 2026, 18:50 UTC
Immunovant Reports Q2 2026 Financial Results and IMVT-1402 Clinical Data Motley Fool · November 10, 2026, 01:43 UTC
Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug Motley Fool · November 8, 2026, 15:15 UTC
Acumen Pharmaceuticals Expects Phase II Alzheimer's Trial Results in November 2026 Motley Fool · November 5, 2026, 01:48 UTC
Moderna and Merck Face Manufacturing Challenges for Promising Personalized Cancer Vaccine Motley Fool · November 3, 2026, 20:52 UTC
Amgen's Imdelltra Shows Significant Efficacy in Advanced Lung Cancer Treatment Motley Fool · November 2, 2026, 17:25 UTC
American Association for Physician Leadership Releases New Book on Systems Thinking and Strategic Change PR Newswire · October 30, 2026, 12:51 UTC
Pennsylvania Reports Nearly 1,400 Measles Cases and Five Deaths Seeking Alpha · October 29, 2026, 16:18 UTC